Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Urothelial Cancer
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1030
- Registration Number
- NCT04223856
- Locations
- πΊπΈ
Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona, United States
πΊπΈArizona Oncology Associates PD - HOPE, Tucson, Arizona, United States
πΊπΈProvidence St Joseph Medical Center, Burbank, California, United States
A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites
- Conditions
- Allergic to House Dust Mites
- Interventions
- Biological: Placebo
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04184895
- Locations
- π©πͺ
Site DE49001, Berlin, Germany
π©πͺSite DE49002, Hannover, Germany
An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
- Conditions
- Locally Advanced or Metastatic Urothelial Carcinoma (UC)
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT04136808
- Locations
- πΊπΈ
UCLA Hematology Oncology, Los Angeles, California, United States
πΊπΈJohn Wayne Cancer Institute, Santa Monica, California, United States
πΊπΈSt. Joseph Heritage Medical Group, Santa Rosa, California, United States
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04096157
- Locations
- πΊπΈ
Parexel International, Baltimore, Maryland, United States
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04094519
- Locations
- π²π©
Site MD37301, Chisinau, Moldova, Republic of
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT04079296
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
πΊπΈMemorial Healthcare System-West, Pembroke Pines, Florida, United States
πΊπΈNYU Langone Health, New York, New York, United States
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT04077879
- Locations
- πΊπΈ
California Clinical Trials Medical Group / Parexel, Glendale, California, United States
A Study to Assess ASP2713 in Healthy Subjects
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT04017208
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 501
- Registration Number
- NCT04003142
- Locations
- πΊπΈ
Mesa Obstetricians and Gynecologists, Mesa, Arizona, United States
πΊπΈPrecision Trials, Phoenix, Arizona, United States
πΊπΈVisions Clinical Research - Tuscon, Tucson, Arizona, United States
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 527
- Registration Number
- NCT04003155
- Locations
- πΊπΈ
SEC Clinical Research, Andalusia, Alabama, United States
πΊπΈCentral Research Associates, Birmingham, Alabama, United States
πΊπΈAchieve Clinical Research, LLC, Ensley, Alabama, United States